Pure Global
NCT01705106

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

A Drug-drug Interaction Study of Capecitabine and Celecoxib in Patients With Advanced Solid Malignancies
University of Chicago·Phase 1·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
capecitabine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Chicago
Location
Chicago, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Aug 29, 2012
End date
Feb 10, 2016
Enrollment
21 participants
Primary outcome

AUC of Celecoxib on Combination Therapy (Day 14) and AUC of Celecoxib on Celecoxib Monotherapy(Day 7)

Summary

This clinical trial studies capecitabine and celecoxib in treating patients with solid
 malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy,
 such as capecitabine, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor
 cells by blocking some of the enzymes needed for cell growth. Giving capecitabine and
 celecoxib together may be an effective treatment for solid malignancies.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01705106
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01705106 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Chicago and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 21 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.